Recombinetics Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 38
Employees
  • Latest Deal Type
  • Debt - PPP
  • Latest Deal Amount
  • $766K
Latest Deal Amount
  • Investors
  • 4

Recombinetics General Information

Description

Developer of gene editing technologies designed to improve human health through advanced disease models and regenerative medicine. The company's technologies manipulates deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offers gene repair and gene editing tools, enabling biomedical research, livestock productivity, animal agriculture and livestock vertical markets to modify animal genomes accurately and efficiently.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Primary Office
  • 3388 Collins Drive
  • Eagan, MN 55121
  • United States
+1 (612) 000-0000

Recombinetics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Recombinetics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Debt - PPP 14-Apr-2020 $766K 000.00 Completed Generating Revenue
11. Grant 000.00 000.00 Completed Generating Revenue
10. Later Stage VC 000.00 000.00 Completed Generating Revenue
9. Later Stage VC (Series A) 18-Sep-2018 000.00 000.00 Completed Generating Revenue
8. Later Stage VC 14-Nov-2016 0000 000.00 Completed Generating Revenue
7. Grant 13-Oct-2016 00000 00.000 Completed Generating Revenue
6. Later Stage VC 28-Oct-2014 00000 00.000 Completed Generating Revenue
5. Early Stage VC 06-Aug-2013 0000 00.000 Completed Generating Revenue
4. Early Stage VC (Series A) 13-Mar-2013 $330K $1.68M Completed Generating Revenue
3. Grant $1M $1.35M Completed Generating Revenue
To view Recombinetics’s complete valuation and funding history, request access »

Recombinetics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of gene editing technologies designed to improve human health through advanced disease models and regenerative
Biotechnology
Eagan, MN
38 As of 2020
000.00
000000000 - 000.00

00000000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000000000000
Cambridge, MA
0000 As of 0000
00000
00000000 00000

00000 00

minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Dui
0000000000000
Philadelphia, PA
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Recombinetics Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bluebird Bio Formerly VC-backed Cambridge, MA 0000 00000 00000000 00000
00000 000000000000 Formerly VC-backed Philadelphia, PA 000 00000 000000&0 00000
00000 000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
00000000 000000000 Formerly VC-backed Cambridge, MA 000 0000 000000 - 000 0000
00000 0000 0000 Venture Capital-Backed Pittsburgh, PA 0 00.000 0000000000 0 00.000
You’re viewing 5 of 15 competitors. Get the full list »

Recombinetics Executive Team (23)

Name Title Board Seat Contact Info
Mark Platt President & Co-Chief Executive Officer
Tammy Lee stanoch President & Co-Chief Executive Officer
David Aberle Chief Financial Officer & Vice President of Finance
Dan Carlson Ph.D Chief Scientific Officer & Senior Vice President, Research & Development
Walter Lowe Ph.D Chief Scientific Officer of Regenevida
You’re viewing 5 of 23 executive team members. Get the full list »

Recombinetics Board Members (17)

Name Representing Role Since
Bill Farrell Self Board Member 000 0000
Cliff Hoffman Self Director 000 0000
David Largaespada Ph.D Self Chief Scientific Officer of Surrogen & Board Member 000 0000
Douglas Keeth Self Director 000 0000
Jerry Arndt Recombinetics Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Recombinetics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Recombinetics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
Newlin Venture Capital Minority 000 0000 000000 0
United States Department of Agriculture Government 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0
To view Recombinetics’s complete investors history, request access »

Recombinetics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000000 08-Oct-2020 000000000000000000 Other Healthcare Services 0000 00000
To view Recombinetics’s complete acquisitions history, request access »